When compared to a control group of patients previously treated with trastuzumab-based therapy without prior exposure to pertuzumab, there were no significant differences in clinical activity or adverse events helping to solidify T-DM1 as a second-line therapy for patients with metastatic HER2-positive breast cancer in patients previously treated with dual anti-HER2 therapy. Here, ERBB2 is linked to breast carcinoma.